AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Camurus

Board/Management Information Oct 27, 2021

3021_rns_2021-10-27_14287c40-afe0-497d-95d4-78f4f0e61c06.pdf

Board/Management Information

Open in Viewer

Opens in native device viewer

PRESS RELEASE

Camurus' Nomination Committee appointed for the Annual General Meeting 2022

Lund — 27 October 2021 — Camurus today announced that the Nomination Committee for the Annual General Meeting, AGM, 2022 consists of the following persons, who together represent about 49 percent of the total number of shares and votes in Camurus based on the last known shareholder information:

  • Per Sandberg, appointed by Sandberg Development AB,
  • Max Mitteregger, appointed by Gladiator,
  • Arne Lööw, appointed by Fjärde AP-fonden, and
  • Per Olof Wallström, Chairman of the Board

The Nomination Committee's proposals will be presented in the Notice to the AGM 2022 and on Camurus' website, www.camurus.com.

Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company's address, Ideon Science Park, SE-223 70, Lund, Sweden. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 10 February 2022, to ensure that the proposals can be adequately considered by the Nomination Committee.

The AGM 2022 in Camurus will be held at 5:00 pm CET on 12 May 2022 in Lund. Shareholders who want to have a matter addressed at the AGM 2022 must submit such a proposal to the same address as above (subject "Annual General Meeting 2022") by 24 March 2022 at the latest.

About Camurus

Camurus is a Swedish research-based pharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit www.camurus.com.

For more information

Per Olof Wallström, Chairman of the Board Tel. +46 709 42 95 20 [email protected]

The information was submitted for publication at 07:00 am CET on 27 October 2021.

Talk to a Data Expert

Have a question? We'll get back to you promptly.